Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 9/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696594 | 1.00 | TRPA1 (0.46) | TRPA1NPC1MTORRAB9APOLB | |
| SCHEMBL3221444 | 0.82 | TRPA1 (0.40) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3221435 | 0.82 | TRPA1 (0.40) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3231075 | 0.82 | NR1H2 (0.51) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3231552 | 0.82 | NR1H2 (0.51) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3231078 | 0.82 | NR1H2 (0.51) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3213143 | 0.75 | ITGB3 (0.48) | — | |
| SCHEMBL3225846 | 0.74 | CDC25A (0.37) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL6700330 | 0.74 | CDC25A (0.37) | TRPA1NPC1MTORRAB9ACDC25A | |
| SCHEMBL3227107 | 0.72 | NR1H2 (0.52) | TRPA1NPC1MTORRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | TRPA1 1431/4885NPC1 3553/4885MTOR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.